TY - JOUR
T1 - Prognostic value of depression and anxiety on breast cancer recurrence and mortality
T2 - a systematic review and meta-analysis of 282,203 patients
AU - Wang, Xuan
AU - Wang, Neng
AU - Zhong, Lidan
AU - Wang, Shengqi
AU - Zheng, Yifeng
AU - Yang, Bowen
AU - Zhang, Juping
AU - Lin, Yi
AU - Wang, Zhiyu
N1 - Funding Information:
This work was supported by the National Natural Science Foundation of China under Grant [81873306, 81573651, 81973526, 81703749, 81703764]; Guangdong Science and Technology Department under Grant [2016A030306025]; Guangdong High-level Personnel of Special Support Program under Grant [A1-3002-16-111-003]; Department of Education of Guangdong Province under Grant [2018KZDXM022, A1-2606-19-111-009]; Guangdong traditional Chinese medicine bureau project under Grant [20181132, 20182044, 20201132]; the Ph.D. Start-up Fund of Natural Science Foundation of Guangdong Province under Grant [2017A030310213, 2018A030310506]; Science and Technology Planning Project of Guangdong Province under Grant [2017B030314166]; Guangzhou science and technology project under Grant [201904010407]; The Specific Research Fund for TCM Science and Technology of Guangdong provincial Hospital of Chinese Medicine under Grant [YN2018MJ07, YN2018QJ08], and the Foundation for Young Scholars of Guangzhou University of Chinese Medicine under Grant [QNYC20190101].
Publisher copyright:
© The Author(s) 2020.
PY - 2020/12
Y1 - 2020/12
N2 - Depression and anxiety are common comorbidities in breast cancer patients. Whether depression and anxiety are associated with breast cancer progression or mortality is unclear. Herein, based on a systematic literature search, 17 eligible studies involving 282,203 breast cancer patients were included. The results showed that depression was associated with cancer recurrence [1.24 (1.07, 1.43)], all-cause mortality [1.30 (1.23, 1.36)], and cancer-specific mortality [1.29 (1.11, 1.49)]. However, anxiety was associated with recurrence [1.17 (1.02, 1.34)] and all-cause mortality [1.13 (1.07, 1.19)] but not with cancer-specific mortality [1.05 (0.82, 1.35)]. Comorbidity of depression and anxiety is associated with all-cause mortality [1.34 (1.24, 1.45)] and cancer-specific mortality [1.45 (1.11, 1.90)]. Subgroup analyses demonstrated that clinically diagnosed depression and anxiety, being female and of younger age (<60 years), and shorter follow-up duration (≤5 years) were related to a poorer prognosis. Our study highlights the critical role of depression/anxiety as an independent factor in predicting breast cancer recurrence and survival. Further research should focus on a favorable strategy that works best to improve outcomes among breast cancer patients with mental disorders.
AB - Depression and anxiety are common comorbidities in breast cancer patients. Whether depression and anxiety are associated with breast cancer progression or mortality is unclear. Herein, based on a systematic literature search, 17 eligible studies involving 282,203 breast cancer patients were included. The results showed that depression was associated with cancer recurrence [1.24 (1.07, 1.43)], all-cause mortality [1.30 (1.23, 1.36)], and cancer-specific mortality [1.29 (1.11, 1.49)]. However, anxiety was associated with recurrence [1.17 (1.02, 1.34)] and all-cause mortality [1.13 (1.07, 1.19)] but not with cancer-specific mortality [1.05 (0.82, 1.35)]. Comorbidity of depression and anxiety is associated with all-cause mortality [1.34 (1.24, 1.45)] and cancer-specific mortality [1.45 (1.11, 1.90)]. Subgroup analyses demonstrated that clinically diagnosed depression and anxiety, being female and of younger age (<60 years), and shorter follow-up duration (≤5 years) were related to a poorer prognosis. Our study highlights the critical role of depression/anxiety as an independent factor in predicting breast cancer recurrence and survival. Further research should focus on a favorable strategy that works best to improve outcomes among breast cancer patients with mental disorders.
UR - http://www.scopus.com/inward/record.url?scp=85089673495&partnerID=8YFLogxK
U2 - 10.1038/s41380-020-00865-6
DO - 10.1038/s41380-020-00865-6
M3 - Review article
C2 - 32820237
AN - SCOPUS:85089673495
SN - 1359-4184
VL - 25
SP - 3186
EP - 3197
JO - Molecular Psychiatry
JF - Molecular Psychiatry
IS - 12
ER -